Growth Hormone Deficiency – Executive Insights – Growth hormone deficiency: Executive Insights (US)
Growth hormone deficiency (GHD) is characterized by slow growth or absence of growth, short stature, and absent or delayed sexual development. Accurately testing for GHD is challenging and often cumbersome. Recombinant human growth hormone (rhGH) has been the mainstay treatment for GHD since 1985. The current landscape for rhGH therapy is very competitive; several products are approved, and only a few agents are in late-phase clinical trials. Each of the products in development aims to improve the frequency of dosing, thereby reducing the burden on patients.
Questions answered
- What is the prevalence of GHD? How are U.S. GHD patients managed?
- What are the key areas of unmet need and opportunities in the treatment of GHD?
- Which therapies are in late-phase development for GHD? What is the potential impact of new launches, and how will these therapies affect future opportunity in the treatment of GHD?
- What are the key drivers of, and limitations on, the market today and in the future?
Product description
Executive Insights provides indication-specific market intelligence withworld-class epidemiology and keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
Geography: United States
Primary research: Three KOL interviews from March 2023
Key companies covered: Novo Nordisk, Eli Lilly, Roche / Genentech, Pfizer, Sandoz, Merck KGaA, Ferring, Ascendis Pharma, Lumos Pharma
Key drugs covered: Norditropin, Genotropin / Genotropin MiniQuick, Omnitrope, Humatrope, Nutropin, Saizen, Zomacton, Skytrofa, Somapacitan (Sogroya), Somatrogon (Ngenla), Ibutamoren mesylate (LUM 201)
